Yuviwel (navepegritide)
Ascendis Pharma (ASND)
ApprovedFeb 27, 2026
Marketer take
A once-weekly option in achondroplasia versus daily Voxzogo injections, with oral infigratinib due Feb 4, 2027, so pediatric endocrinologists and families will weigh dosing frequency and route.
- Sponsor company
- Ascendis Pharma (ASND)
- Indication
- To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
- Therapeutic area
- Endocrinology, Rare disease
- Event
- FDA approval
- Date
- Feb 27, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?